Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.29 and traded as high as $2.85. Sonoma Pharmaceuticals shares last traded at $2.66, with a volume of 151,920 shares traded.

Sonoma Pharmaceuticals Stock Down 1.1 %

The company has a market capitalization of $3.56 million, a PE ratio of -0.53 and a beta of 1.41. The firm has a 50-day moving average of $2.71 and a two-hundred day moving average of $2.29.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.59) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 59.58% and a negative net margin of 27.21%. The firm had revenue of $3.58 million for the quarter. On average, equities research analysts expect that Sonoma Pharmaceuticals, Inc. will post -4 EPS for the current year.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.